Cytokinetics Inc
Research Cytokinetics Inc (CYTK) on Bullrun: market cap USD 8.73B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCYTK
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.73B
- Financial periodQ2 2026
- RevenueUSD 28.62M
- Net income-USD 198.76M
- Free cash flow-USD 164.17M
- Gross margin80.5%
Valuation Snapshot
latest market cap is USD 8.73B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 88.04M | -USD 784.96M | -USD 534.82M | -372.5% | -6.54 | USD 122.52M | USD 287.57M | -USD 659.63M |
| FY2024 | USD 18.47M | -USD 589.53M | -USD 399.80M | -1737.2% | -5.26 | USD 94.86M | USD 104.75M | -USD 135.37M |
| FY2023 | USD 7.53M | -USD 526.24M | -USD 415.75M | -4284.1% | -5.45 | USD 113.02M | USD 68.46M | -USD 386.32M |
| FY2022 | USD 94.59M | -USD 388.96M | -USD 310.85M | -154.6% | -4.33 | USD 65.58M | USD 64.77M | -USD 107.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 8.73B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.81B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.56B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 8.19B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.34B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.87B | n/a | n/a | n/a |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM;
ETFs that hold Cytokinetics Inc
Cytokinetics Inc is one of the ten largest holdings of 5 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| State Street SPDR Russell 2000 US Small Cap UCITS ETF | 0.33% | 0.30% |
| Xtrackers Russell 2000 UCITS ETF 1C | 0.35% | 0.30% |
| iShares Ageing Population UCITS ETF USD (Acc) | 0.61% | 0.40% |
| Vanguard Russell 2000 U.S. Small-Cap UCITS ETF USD Acc | 0.33% | 0.20% |
| State Street SPDR Russell 2000 US Small Cap UCITS ETF EUR Hedged Acc | 0.30% | 0.35% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cytokinetics Inc's market cap?
Cytokinetics Inc's market capitalization is USD 8.73B.
What does Cytokinetics Inc do?
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.